65900 Federal Register / Vol. 70, No. 210 / Tuesday, November 1, 2005 / Notices 

Region 5, Ground Water and Drinking 

Water Branch (WG–15J), 77 West 

Jackson Boulevard, Chicago, Illinois 

60604, between the hours of 9 a.m. and 

4:30 p.m., Monday through Friday. 

FOR FURTHER INFORMATION CONTACT: 

Margarita Chacon, EPA Region 5, 

Ground Water and Drinking Water 

Branch, at the address given above, by 

telephone at (312) 886–0225, or at 

chacon.margarita@epa.gov. 

Authority: (Section 1413 of the Safe 

Drinking Water Act, as amended, 42 U.S.C. 

3006–2 (1996), and 40 CFR part 142 of the 

National Primary Drinking Water 

Regulations). 

Dated: October 24, 2005. 

Norman Niedergang, 

Acting Regional Administrator, Region 5. 

[FR Doc. 05–21748 Filed 10–31–05; 8:45 am] 

BILLING CODE 6560–50–P 

EXPORT-IMPORT BANK OF THE 

UNITED STATES 

Sunshine Act Meeting 

ACTION: Notice of a Partially Open 

Meeting of the Board of Directors of the 

Export-Import Bank of the United 

States. 

TIME AND PLACE: Friday, November 4, 

2005 at 11:30 a.m. The Meeting will be 

held at Ex-Im Bank in Room 1143, 811 

Vermont Avenue, NW., Washington, DC 

20571. 

OPEN AGENDA ITEM: Ex-Im Bank SubSaharan Africa Advisory Committee for 

2006. 

PUBLIC PARTICIPATION: The meeting will 

be open to public participation for Item 

No. 1 only. 

FOR FURTHER INFORMATION CONTACT: For 

further information, contact: Office of 

the Secretary, 811 Vermont Avenue, 

NW., Washington, DC 20571 (Tele. No. 

202–565–3957). 

Howard A. Schweitzer, 

General Counsel (Acting). 

[FR Doc. 05–21860 Filed 10–28–05; 12:58 

pm] 

BILLING CODE 6690–01–M 

FEDERAL RESERVE SYSTEM 

Change in Bank Control Notices; 

Acquisition of Shares of Bank or Bank 

Holding Companies 

The notificants listed below have 

applied under the Change in Bank 

Control Act (12 U.S.C. 1817(j)) and 

§ 225.41 of the Board’s Regulation Y (12 

CFR 225.41) to acquire a bank or bank 

holding company. The factors that are 

considered in acting on the notices are 

set forth in paragraph 7 of the Act (12 

U.S.C. 1817(j)(7)). 

The notices are available for 

immediate inspection at the Federal 

Reserve Bank indicated. The notices 

also will be available for inspection at 

the office of the Board of Governors. 

Interested persons may express their 

views in writing to the Reserve Bank 

indicated for that notice or to the offices 

of the Board of Governors. Comments 

must be received not later than 

November 16, 2005. 

A. Federal Reserve Bank of 

Richmond (A. Linwood Gill, III, Vice 

President) 701 East Byrd Street, 

Richmond, Virginia 23261–4528: 

1. Charles F. Sposato Flint Trust and 

trustee Mark Wayne Saunters, Elkton, 

Maryland; to control voting shares of 

Cecil Bancorp, Inc., Elkton, Maryland, 

and thereby indirectly acquire voting 

shares of Cecil Federal Bank, Elkton, 

Maryland. 

Board of Governors of the Federal Reserve 

System, October 27, 2005. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. E5–6024 Filed 10–31–05; 8:45 am] 

BILLING CODE 6210–01–S 

FEDERAL RESERVE SYSTEM 

Notice of Proposals to Engage in 

Permissible Nonbanking Activities or 

to Acquire Companies that are 

Engaged in Permissible Nonbanking 

Activities 

The companies listed in this notice 

have given notice under section 4 of the 

Bank Holding Company Act (12 U.S.C. 

1843) (BHC Act) and Regulation Y (12 

CFR Part 225) to engage de novo, or to 

acquire or control voting securities or 

assets of a company, including the 

companies listed below, that engages 

either directly or through a subsidiary or 

other company, in a nonbanking activity 

that is listed in § 225.28 of Regulation Y 

(12 CFR 225.28) or that the Board has 

determined by Order to be closely 

related to banking and permissible for 

bank holding companies. Unless 

otherwise noted, these activities will be 

conducted throughout the United States. 

Each notice is available for inspection 

at the Federal Reserve Bank indicated. 

The notice also will be available for 

inspection at the offices of the Board of 

Governors. Interested persons may 

express their views in writing on the 

question whether the proposal complies 

with the standards of section 4 of the 

BHC Act. Additional information on all 

bank holding companies may be 

obtained from the National Information 

Center Web site at www.ffiec.gov/nic/. 

Unless otherwise noted, comments 

regarding the applications must be 

received at the Reserve Bank indicated 

or the offices of the Board of Governors 

not later than November 16, 2005. 

A. Federal Reserve Bank of Atlanta 

(Andre Anderson, Vice President) 1000 

Peachtree Street, NE., Atlanta, Georgia 

30303: 

1. Cornerstone Bancshares, Inc., and 

EFI Acquisition, Inc., both of 

Chattanooga, Tennessee, to acquire 

voting shares of Eagle Financial, LLC 

and Eagle Funding, LLC, both of 

Chattanooga, Tennessee, and thereby 

engage in providing factoring services to 

small business and services as a loan 

broker serving as a facilitator to small 

businesses, pursuant to section 

225.28(b)(1) of Regulation Y. 

Board of Governors of the Federal Reserve 

System, October 27, 2005. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. E5–6025 Filed 10–31–05; 8:45 am] 

BILLING CODE 6210–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Meeting of the Presidential Advisory 

Council on HIV/AIDS 

AGENCY: Department of Health and 

Human Services, Office of the Secretary, 

Office of Public Health and Science. 

ACTION: Notice. 

SUMMARY: As stipulated by the Federal 

Advisory Committee Act, the 

Department of Health and Human 

Services (DHHS) is hereby giving notice 

that the Presidential Advisory Council 

on HIV/AIDS (PACHA) will hold a 

meeting. This meeting is open to the 

public. A description of the Council’s 

functions is included also with this 

notice. 

Date and Time: November 14, 2005, 

8:30 a.m. to 5 p.m. 

ADDRESSES: Department of Health and 

Human Services, Hubert H. Humphrey 

Building, Room 800, 200 Independence 

Ave., SW., Washington, DC 20201. 

FOR FURTHER INFORMATION CONTACT: 

Joseph Grogan, Esq., Executive Director, 

Presidential Advisory Council on HIV/ 

AIDS, Department of Health and Human 

Services, Hubert H. Humphrey Building, 

200 Independence Avenue, SW., Room 

736E, Washington, DC 20201; or visit 

the Council’s Web site at http:// 

www.pacha.gov. 

Federal Register / Vol. 70, No. 210 / Tuesday, November 1, 2005 / Notices 65901 

SUPPLEMENTARY INFORMATION: PACHA 

was established by Executive Order 

12963, dated June 14, 1995, as amended 

by Executive Order 13009, dated June 

14, 1996. PACHA was established to 

provide advice, information, and 

recommendations to the President 

regarding programs and policies 

intended to (a) promote effective 

prevention of HIV disease, (b) advance 

research on HIV and AIDS, and (c) 

promote quality services to persons 

living with HIV disease and AIDS. 

PACHA was established to serve solely 

as an advisory body to the President and 

the Secretary of Health and Human 

Services. PACHA is composed of not 

more than 21 members. PACHA 

membership is determined by the 

Secretary from individuals who are 

considered authorities with particular 

expertise in, or knowledge of, matters 

concerning HIV/AIDS. 

The agenda for this meeting includes 

the following topics: HIV/AIDS 

prevention, care and treatment, and 

global HIV/AIDS issues. Time will be 

allotted during the meeting for public 

comment. 

Public attendance is limited to space 

available and pre-registration is required 

for both attendance and public 

comment. Any individual who wishes 

to attend and/or comment must register 

on-line at http://www.pacha.gov. 

Individuals who need special 

assistance, such as sign language 

interpretation or other reasonable 

accommodations, should indicate when 

registering on-line. 

Members of the public will have the 

opportunity to provide comments at the 

meeting. Public comment will be 

limited to three (3) minutes per speaker 

and to time available. Written 

testimony, not exceed five (5) pages, 

will be accepted by mail or facsimile at 

202/205–4986. 

Written testimony will not be 

accepted after 5 p.m., Wednesday, 

November 9, 2005. 

Dated: October 26, 2005. 

Joseph Grogan, 

Executive Director, Presidential Advisory 

Council on HIV/AIDS. 

[FR Doc. 05–21714 Filed 10–31–05; 8:45 am] 

BILLING CODE 4150–43–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Statement of Organization, Functions, 

and Delegations of Authority 

Part C (Centers for Disease Control 

and Prevention) of the Statement of 

Organization, Functions, and 

Delegations of Authority of the 

Department of Health and Human 

Services (45 FR 67772–76, dated 

October 14, 1980, and corrected at 45 FR 

69296, October 30, 1980, as amended 

most recently at 69 FR 77756, dated 

December 28, 2004) is amended to 

reorganize the National Center for HIV, 

STD, & TB Prevention. 

Section C–B, Organization and 

Functions, is hereby amended as 

follows: 

Delete in its entirety the following 

titles and functional statements: 

Division of AIDS, STD & TB Laboratory 

Research (CK7), Office of the Director 

(CK71), HIV, Immunology and 

Diagnostics Branch (CK72), HIV 

Immunology and Diagnostics Branch 

(CK73), Sexually Transmitted Infectious 

Diseases Branch (CK74), Tuberculosis/ 

Mycobacteriology Branch (CK75). 

Following the Training and Health 

Communication Branch (CK37), 

Division of STD Prevention (CK3), insert 

the following: 

Laboratory Reference and Research 

Branch, (CK38). (1) Performs research 

on the pathogenesis, genetics, and 

immunology of syphilis and other 

treponematoses, gonococcal and 

chlamydial infections, chancroid, 

genital herpes, donovanosis, bacterial 

vaginosis and trichomoniasis; (2) 

conducts and participates in clinical, 

field, and laboratory research to 

develop, evaluate, and improve 

laboratory methods used in the 

diagnosis and epidemiology of these 

sexually transmitted infections (STIs); 

(3) provides consultation and reference/ 

diagnostic services for these STIs; (4) 

conducts laboratory-based surveillance 

for and research on the genetics of 

antimicrobial resistance in Neisseria 

gonorrhoeae; (5) serves as the WHO 

International Collaborating Center for 

Reference and Research in Syphilis 

Serology; and (6) provides consultation 

and laboratory support for international 

activities. 

Following the International Research 

and Programs Branch (CK47), Division 

of Tuberculosis Elimination (CK4), 

insert the following: 

Mycobacteriology Branch (HCK48). (1) 

Provides laboratory support for 

epidemic investigations, surveillance 

activities, and special studies of 

tuberculosis and other mycobacteriacaused diseases; (2) administers 

contracts to provide Mycobacterium 

tuberculosis genotyping, maintains a 

national database of genotypes, and 

conducts operational research to 

implement genotyping; (3) develops and 

evaluates new methods to subtype 

mycobacteria for epidemiologic studies; 

(4) serves as primary CDC focus for 

diagnostic mycobacteriology laboratory 

services and for laboratory aspects of 

nontuberculosis Mycobacterium species 

and of Hansen disease (leprosy); (5) 

administers grants and cooperative 

agreements with states and others to 

upgrade laboratory activities and 

provide special services; (6) provides 

reference diagnostic services, 

consultation, technical assistance, and 

training to State, Federal, and municipal 

public health laboratories; (7) provides 

laboratory support, reference services, 

assessment, consultation, and training 

for CDC’s international tuberculosis 

activities; (8) develops, evaluates, or 

improves conventional and molecular 

methods for the detection, classification, 

identification, characterization, and 

susceptibility testing of mycobacteria 

and mycobacteria-caused diseases; (9) 

conducts studies to define the role of 

bacterial virulence factors, host factors, 

and pathogenic and immunologic 

mechanisms in disease processes and 

protective immunity and develops, 

evaluates, and improves immunologic 

methods for the diagnosis and 

prevention of mycobacteria-caused 

diseases; (10) develops tissue culture 

and animal models of mycobacteriacaused diseases and conducts studies on 

chemotherapy, immunotherapy, 

pathogenesis, pathology, and vaccines 

for mycobacteria-caused diseases; (11) 

conducts studies on the isolation, 

taxonomy, and ecology of mycobacteria 

and develops tests to identify new 

species; (12) conducts and supports 

studies to characterize newly emerging 

pathogenic species of Mycobacterium 

and associated diseases. 

Following the HIV Incidence and 

Case Surveillance Branch (CK56), 

Division of HIV, AIDS Prevention—

Surveillance and Epidemiology (CK5), 

insert the following: 

HIV and Retrovirology Laboratory 

Branch (HCK57). (1) Conducts studies of 

human immunodeficiency viruses 

(HIVs) and other human and zoonotic 

retroviruses, including the diseases they 

cause, their modes of transmission, and 

the means for their control through 

virus detection, isolation, and 

characterization by virologic, molecular, 

and cellular biologic methods; (2)